Commercializing medical device innovation

Medical technology in action Credit: Institute for Manufacturing

(Medical Xpress) -- New medical devices take a long time to reach the market – and many never make it. Jon Johnson, a researcher at Cambridge’s Institute for Manufacturing, is looking at ways of making the process of commercialisation more efficient.

Biotechnology and healthcare developments require huge financial and resource investment, in-depth research and clinical trials. Consequently, these developments involve a complex multidisciplinary structure, which is inherently full of risks and uncertainty. Jon Johnson, a researcher in the Institute for Manufacturing, is looking at the process by which medical devices are taken from early concept through to commercialization, including technology confidence, early testing, investment implications, and regulatory compliance.

The feasibility stage of design is critical, and there is currently little guidance for practitioners to navigate this inherently complex set of activities. In a similar fashion to high-tech industries, the medical sector has huge incentives to increase development efficiency, reduce time to market and increase profits. The medical industry has unique requirements, including extensive science and technology management, considerable testing, clinical trials and regulatory control. When addressing scientific and technical innovation within this industry, it is critical to have a clear understanding of the clinical need, market potential and technical risks.

A major challenge lies in the process of determining technical feasibility without demonstrating preliminary function and early test data. These requirements mean that the development of medical devices is often extremely expensive, with project schedules taking between four and ten years. There is genuine pressure on industry to reduce these costs and improve time to market by reducing the inherent risks at the feasibility stage of development. Therefore it is necessary to gain confidence within the technology as soon as possible and preferably before investing excessively.

Johnson is particularly interested in the early stages of medical device development – the early feasibility studies which determine whether a technology is viable years down the line – and how designers, engineers and scientists work closely with medical practitioners, healthcare providers and patients. He believes that this stage offers the biggest potential to test concept viability, establish whether the technology will function sufficiently, meet critical user needs, identify genuine health benefits and determine regulatory viability.

“According to the FDA (Food and Drug Administration), a vast majority of investigational products never make it through clinical approval and market adoption.  This failure represents a huge loss of time and investment,” said Johnson.

What is needed is better evaluation at the early stages of development. In order to understand how a product makes the journey from first concept to commercial adoption, Johnson has been working with eight leading medical organisations to track this complex process. The output from this study includes an original approach by which companies can better analyse, manage and measure the success of early technology innovation within the healthcare sector. Such studies would also improve regulatory viability, provide significant cost savings and maximise benefits to the healthcare industry.

Jon Johnson is a PhD candidate in the Institute for Manufacturing, Department of Engineering at the University of Cambridge. He is supervised by Dr James Moultrie.

add to favorites email to friend print save as pdf

Related Stories

Cancer drugs: better, cheaper

Jun 04, 2012

Cancer drug development is known to be too slow, costly and fraught with failure. Now the U.S. Food and Drug Administration is issuing recommendations for breast cancer trials that would substantially accelerate patient access ...

FDA plans modest changes to medical device system

Jan 19, 2011

(AP) -- The Food and Drug Administration is laying out plans to update the 35-year-old system used to approve most medical devices, which has been subject to increasing criticism by public safety advocates.

Recommended for you

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments